After struggling to find support for its inactivated whole-virus COVID-19 vaccine candidate VLA2001, French vaccine company Valneva SE (Nasdaq:VALN; Euronext Paris:VLA) has received a €90.5 ($95) million investment from Pfizer (NYSE:PFE), which amounts to 8.1% of the company’s share capital at a price of €9.49 per share. The Saint-Herblain, France–based company plans on using the…
Valneva agrees to terminate UK supply agreement for COVID-19 vaccine
French vaccine company Valneva SE (Nasdaq:VALN; Euronext Paris:VLA) has reached a settlement agreement with regulators in the United Kingdom related to the termination of a supply agreement for its COVID-19 vaccine candidate. The company is attempting to salvage a COVID-19 vaccine deal with the EU after regulators announced plans to terminate an Advance Purchase Agreement (APA) related to the vaccine…
Valneva aims to salvage COVID-19 vaccine deal with EU
French vaccine company Valneva SE (Nasdaq:VALN; Euronext Paris:VLA) is hoping to change the European Commission’s (EC) mind after regulators notified the firm that they intend to terminate an Advance Purchase Agreement (APA) for its inactivated whole-virus COVID-19 vaccine candidate VLA2001. VALN shares fell 15% to $20.00. In February, Valneva announced that it expected authorization for…
Valneva anticipates EMA nod for its COVID-19 vaccine candidate in April
French vaccine company Valneva SE (Nasdaq:VALN; Euronext Paris:VLA) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has sent the company a “small set” of questions related to its VLA2001 COVID-19 vaccine candidate. The firm announced on February 25 that CHMP had sent the company a…
Valneva shares surge 30% after announcing its vaccine candidate neutralized omicron in neutralizing antibody study
Valneva SE (NSDQ:VALN) announced promising preliminary lab results involving recipients of its inactivated VLA2001 COVID-19 vaccine. In a pseudovirus neutralization assay involving sera from 30 volunteers in the Phase 1/2 trial VLA2001-201, all samples had neutralizing antibodies against the ancestral virus and the delta variant. In addition, 87% (26 samples) had neutralizing antibodies to omicron.…
Pfizer, Valneva to co-develop Lyme disease vaccine
Pfizer and Valneva recently announced that they will collaborate on developing Valneva’s Lyme disease vaccine candidate VLA15, presently in Phase 2 clinical studies. Valneva is eligible to receive a total of $308 million, including $130 million upfront, according to an April 30 news release. Get the full story on our WTWH Media sister site R&D…